These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15623615)
21. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mhaidat NM; Wang Y; Kiejda KA; Zhang XD; Hersey P Mol Cancer Ther; 2007 Feb; 6(2):752-61. PubMed ID: 17308071 [TBL] [Abstract][Full Text] [Related]
22. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Chi KC; Wallis AE; Lee CH; De Menezes DL; Sartor J; Dragowska WH; Mayer LD Breast Cancer Res Treat; 2000 Oct; 63(3):199-212. PubMed ID: 11110054 [TBL] [Abstract][Full Text] [Related]
23. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680 [TBL] [Abstract][Full Text] [Related]
24. A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells. Stessl M; Marchetti-Deschmann M; Winkler J; Lachmann B; Allmaier G; Noe CR J Proteomics; 2009 Aug; 72(6):1019-30. PubMed ID: 19523545 [TBL] [Abstract][Full Text] [Related]
25. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. Lopes de Menezes DE; Hu Y; Mayer LD J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513 [TBL] [Abstract][Full Text] [Related]
26. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Hu Q; Bally MB; Madden TD Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306 [TBL] [Abstract][Full Text] [Related]
27. G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. Stein CA; Wu S; Voskresenskiy AM; Zhou JF; Shin J; Miller P; Souleimanian N; Benimetskaya L Clin Cancer Res; 2009 Apr; 15(8):2797-807. PubMed ID: 19351753 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Leonetti C; Biroccio A; D'Angelo C; Semple SC; Scarsella M; Zupi G Prostate; 2007 Sep; 67(13):1475-85. PubMed ID: 17654511 [TBL] [Abstract][Full Text] [Related]
29. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659 [TBL] [Abstract][Full Text] [Related]
31. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472 [TBL] [Abstract][Full Text] [Related]
32. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Heere-Ress E; Thallinger C; Lucas T; Schlagbauer-Wadl H; Wacheck V; Monia BP; Wolff K; Pehamberger H; Jansen B Int J Cancer; 2002 May; 99(1):29-34. PubMed ID: 11948488 [TBL] [Abstract][Full Text] [Related]
33. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637 [TBL] [Abstract][Full Text] [Related]
35. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel. Losert D; Pratscher B; Soutschek J; Geick A; Vornlocher HP; Müller M; Wacheck V Anticancer Drugs; 2007 Aug; 18(7):755-61. PubMed ID: 17581297 [TBL] [Abstract][Full Text] [Related]
36. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Frankel SR Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157 [TBL] [Abstract][Full Text] [Related]
37. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma. Benimetskaya L; Wittenberger T; Stein CA; Hofmann HP; Weller C; Lai JC; Miller P; Gekeler V Clin Cancer Res; 2004 Jun; 10(11):3678-88. PubMed ID: 15173074 [TBL] [Abstract][Full Text] [Related]
39. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468 [TBL] [Abstract][Full Text] [Related]
40. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]